This study provided long-term follow-up for patients who had previously received a gene therapy called AAV5-hRKp.RPGR for RPGR-related X-linked retinitis pigmentosa. To take part, patients had to have received this gene therapy in the earlier MGT009 study. It was conducted as a non-phase follow-up study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Received AAV5-hRKp.RPGR in the MGT009 Study Exclusion Criteria: * Unwilling or unable to meet with the requirements of the study